Mode
Text Size
Log in / Sign up
N/A N=29 Randomized Double-blind Treatment

Smart Lighting for Nursing Home Residents With Dementia

Alzheimer's Disease and Related Dementias

Enrolled (actual)
29
Serious AEs
3.5%
Results posted
Aug 2025
Primary outcome: Primary: Average Lux During Intervention and Control Periods at the Facility Level — 394.2; 97.4 Lux

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Smart Ambient Bright Light (SABL) (Device); Control (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Penn State University
Primary completion
Oct 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Average Lux During Intervention and Control Periods at the Facility Level
394.2; 97.4
PRIMARY
Average Circadian Stimulation (CS) Level During Intervention and Control Periods at the Facility Level
0.302; 0.097
PRIMARY
Average Lux During Intervention and Control Periods at the Individual Level
406.89; 286.69
PRIMARY
Average Circadian Stimulation (CS) Level During Intervention and Control Periods at the Individual Level
0.36; 0.24
PRIMARY
Change in Agitation During the Intervention and Control Periods
-4.78; -1.48
PRIMARY
Intervention Acceptability
4.10
PRIMARY
Intervention Feasibility
4.40
PRIMARY
Intervention Appropriateness
3.99
SECONDARY
Behavioral and Psychological Symptoms of Dementia (BPSD)
-1.11; -0.07; -1.15; 0.30; -1.04; 0.07
SECONDARY
Affect
0.22; 0.56; 0.26; 0.48; 0.15; 0.44
SECONDARY
Adverse Effects.
0; 0

Summary

This proposed study seeks to develop a smart ambient bright light (SABL) intervention to provide auto-controlled, consistent indoor lighting that incorporates natural daylight. This SABL includes tunable LED lights, photosensors, and controllers. The SABL system has a pre-programmed 24-hour control schedule for illuminance settings to mimic the natural bright-dark cycle. It will automatically adjust the lights to accommodate the daylight effect to minimize staff burden and maximize the LI effect. The SABL will be installed in participants' bedrooms and designated areas in the dining rooms and activity rooms for four weeks. Each participant will wear a personal light monitor to measure the lighting dosage each participant receives. This study will address three aims: 1) pilot test the effect of SABL on reducing agitation in persons with ADRD, 2) evaluate the fidelity of the SABL delivery, and 3) evaluate the feasibility of implementing the SABL. The study will be conducted in two NHs in Pennsylvania. For aims 1 and 2, the investigators will use a crossover, cluster randomized control trial (RCT) and will enroll residents with ADRD and agitation. For aim 3, the investigators will use a mixed methods design and will interview NH stakeholders to evaluate the acceptability, feasibility, and appropriateness of the intervention. This is the first study that incorporates daylight in ambient light interventions and the first study that addresses the measurement, feasibility, and fidelity of lighting interventions. Findings will establish evidence-based implementation strategies and the best design for SABL to reduce agitation for persons with ADRD in NHs.

Eligibility Criteria

Resident participants

Inclusion Criteria

  • Age≥55
  • English speaking
  • Nursing home residency≥3 months
  • Clinical Diagnosis of Alzheimer's Disease and related dementia
  • Presence of agitation over the past week

Exclusion Criteria

  • Major sleep problems
  • Major mental illness
  • Severe vision impairment
  • Severe acute or terminal illness

Staff participants:

Inclusion criteria

  • Age≥18
  • English speaking
  • Employed as a certified nurse assistant (CNA), activity staff, nurse, director of nursing (DON), director of maintenance, administer or other leadership position for at least 3 months. The CNA, activity staff, and nurse must have direct care interactions with the resident participant(s).
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05825404). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search